Bacil Pharma Limited is an India-based pharmaceutical company, which is engaged in the business of manufacturing of pharmaceuticals, medicinal chemicals and botanical products. The Company operates as a manufacturer, exporter, supplier and retailer of a range of anti-anxiety medicine, antihistamines, chemical compound, drugs, and herbal tablets and capsules.

Employees

Sector

Pharmaceuticals

Calendar

10-14 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-10-09	₹24.77	+2.31%	33,415
26-10-08	₹24.21	-4.98%	2,715
26-10-07	₹25.48	-4.78%	25,938
26-10-06	₹26.76	-1.87%	8,735
26-10-05	₹27.27	-0.04%	9,240

Delayed Quote Bombay S.E.

More quotes

Market Closed - Bombay S.E. 06:02:24 2026-10-09 EDT			5-day change	1st Jan Change
24.77 ^INR	+2.31%		-9.20%	-30.50%

09-24	Bacil Pharma Limited Approves the Designation Change of Chaitali Kalpataru from Executive Director to Managing Director	CI
08-12	Bacil Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

Market Cap	356M 3.67M 3.28M 3.05M 2.78M 5.24M 5.26M 36.73M 14.39M 181M 13.79M 13.49M 582M	P/E 2025	66.4x	P/E 2026	43x
Enterprise Value	350M 3.61M 3.23M 3M 2.73M 5.16M 5.18M 36.14M 14.16M 178M 13.57M 13.28M 572M	EV / Sales 2025	-	EV / Sales 2026	-
Free-Float	36.26%	Yield 2025 *	-	Yield 2026	-

09-24	Bacil Pharma Limited Approves the Designation Change of Chaitali Kalpataru from Executive Director to Managing Director	CI
08-12	Bacil Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-10	Bacil Pharma Limited Announces Board Resignations, Effective July 9, 2026	CI
05-22	Bacil Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-13	Bacil Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
12-01	Bacil Pharma Limited Announces Resignation of Bhavana Phoolchand Tak as Company Secretary and Compliance Officer, Effective December 1, 2025	CI
11-13	Bacil Pharma Limited Reports Earnings Results for the Second Quarter Ended September 30, 2025	CI
25-08-25	Bacil Pharma Limited Appoints Vivek Mukesh Yadav as Independent Director, Effective August 25, 2025	CI
25-08-12	Bacil Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-07-22	Bacil Pharma Limited Announces Resignation of Prakash Bhoorchand Shah as Director	CI
25-07-16	Bacil Pharma appoints Chaitali Kalpataru Shah as and CFO	RE
25-07-16	Bacil Pharma Limited Appoints Chaitali Kalpataru Shah as Executive Director, Effective July 16, 2025	CI
25-07-16	Bacil Pharma Limited Appoints Chaitali Kalpataru Shah as Chief Financial Officer, Effective July 16, 2025	CI

1 day	+2.31%
1 week	-9.20%
Current month	-4.99%
1 month	+39.94%
3 months	-35.43%
6 months	-58.28%
Current year	-30.50%

Bacil Pharma Limited Stock

Stocks

524516

INE711D01018

Pharmaceuticals

Valuation: Bacil Pharma Limited

Chart: Bacil Pharma Limited

Latest news: Bacil Pharma Limited

Quotes and Performance

Price Extremes

Managers and Directors: Bacil Pharma Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	23	28.6
1 month	18.83	28.75
Current year	10.65	61.8
1 year	10.65	61.8
3 years	4.68	62.56
5 years	3.67	62.56
10 years	1.57	62.56

Manager	Title	Age	Since
Chaitali Kalpataru Shah CEO	Chief Executive Officer	46	2026-08-24
Dikshant Singh Panwar CMP	Compliance Officer	-	2025-12-18

Director	Title	Age	Since
Chaitali Kalpataru Shah BRD	Director/Board Member	46	2025-07-15
Vivek Mukesh Yadav BRD	Director/Board Member	21	2026-06-29
Omprakash Pyarelal Sonar BRD	Director/Board Member	45	2026-06-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BACIL PHARMA LIMITED	+2.31%	-9.20%	-43.45%	+168.07%	3.59M
ELI LILLY AND COMPANY	+0.83%	+3.19%	+37.87%	+106.25%	1,043B
JOHNSON & JOHNSON	+1.93%	+2.11%	+36.82%	+64.90%	618B
ABBVIE INC.	+1.49%	+5.19%	+19.84%	+85.41%	481B
MERCK & CO., INC.	+2.26%	+0.90%	+66.40%	+39.33%	351B
ROCHE HOLDING AG	+1.45%	+3.50%	+21.87%	+42.64%	338B
NOVARTIS AG	+1.17%	+2.37%	+11.71%	+35.14%	269B
ASTRAZENECA PLC	+0.89%	+1.08%	-7.28%	+10.52%	244B
AMGEN INC.	+1.82%	+2.94%	+40.43%	+52.78%	220B
GILEAD SCIENCES, INC.	+2.77%	+4.44%	+29.49%	+101.40%	182B
Average	+1.58%	+0.45%	+21.37%	+70.65%	374.67B
Weighted average by Cap.	+1.19%	+1.86%	+31.54%	+70.03%

	2025	2026
Net sales	-	-
Net income	4.04M 41.75K 37.29K 34.69K 31.55K 59.58K 59.83K 418K 164K 2.06M 157K 153K 6.61M	15.56M 161K 144K 134K 121K 229K 230K 1.61M 630K 7.93M 604K 590K 25.45M
Net Debt	-26.93M -278K -249K -231K -210K -397K -399K -2.78M -1.09M -13.73M -1.05M -1.02M -44.07M	-5.68M -58.74K -52.46K -48.8K -44.39K -83.81K -84.18K -587K -230K -2.9M -221K -216K -9.3M